Migraine is the primary headache disorder affecting a significant population 
worldwide. Ubrogepant is an orally bioavailable calcitonin gene-related peptide 
(CGRP) receptor antagonist (gepant) approved by the U.S. Food and Drug 
Administration (FDA) for the acute treatment of migraine headaches with or 
without aura in adults. Ubrogepant is the first oral CGRP receptor antagonist 
approved for the acute treatment of migraine. CGRP is an important key mediator 
of migraine pain; CGRP levels have been shown to be significantly higher during 
a migraine attack. Two pivotal phase III clinical trials (ACHIEVE I and ACHIEVE 
II) demonstrated effectiveness and safety of ubrogepant in acute migraine 
attacks. Ubrogepant can be administered as 50- and 100-mg tablets, with a 
maximum dose of 200 mg within 48 h. Besides minimizing pain, the drug is equally 
effective in alleviating migraine-associated symptoms such as nausea, 
photophobia and sound sensitivity. Unlike other gepants, ubrogepant is free from 
hepatotoxicity at the therapeutic doses. In certain cases (1 in 5), a full 
relief of pain was achieved with a single dose of the drug. The molecule is not 
effective as a preventive migraine therapy. The present review discusses the 
background, preclinical and clinical pharmacology, indication and safety of 
ubrogepant for the treatment of migraine attacks.